Advertisement

Volume 131, Issue 5

 

 

February 1, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Lactadherin prevents traumatic brain-associated coagulopathy.  See the article by Yuan Zhou et al.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies
This study addresses a major gap in our knowledge about the timing of the treatment of patients with relapsed AL amyloidosis. The investigators identify a set of criteria that define hematologic progression with adverse outcomes.


Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice
The investigators show that prophylaxis and treatment with the apoptotic cell–scavenging protein lactadherin prevents traumatic brain injury (TBI)–associated coagulopathy in mice, which results in improved outcome of this potentially lethal injury.


Loss of NRF2 function exacerbates the pathophysiology of sickle cell disease in a transgenic mouse model
This report reveals that NRF2, a protein that controls oxidative stress, is important in the control of fetal hemoglobin synthesis and antioxidant response. Lack of NRF2 modulates hemoglobin switching and exacerbates the sickle cell disease phenotype.


Introduction to a review series on hematologic disease at older age
The Series of Reviews published in this issue of Blood is written by leaders in the field and highlights common biologic and clinical concepts related to hematologic disease associated with aging.

The articles in this review series, "Hematologic Disease at Older Age", include the following:


Hematopoietic stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections
This report presents the first proof-of-concept study demonstrating that gene therapy with genetically corrected macrophages may be a therapeutic option for patients with IFNγ receptor 1 (IFNγR1) deficiency.

 


Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus–infected individuals
Hepatitis C virus (HCV) infection frequently causes B-cell lymphoproliferative disease and mixed cryoglobulinemia (MC) that can progress to non-Hodgkin lymphoma (NHL). In these studies, the investigators examine B cells in these patients and show that B-cell clonal expansion is common in HCV patients, likely representing a precursor stage to the development of MC and NHL.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.